Triple-negative breast carcinoma

Researchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …

This early-phase trial tests a personalized vaccine made from a patient's own immune cells (dendritic cells) trained to recognize unique proteins from their leftover breast tumor after standard chemotherapy and surgery. The goal is to see if the vaccine is safe and can boost the …

This study tests a new vaccine called Modi-1, designed to train the immune system to attack cancer cells. It is given as a tiny shot into the skin using a special microneedle device. The trial includes 168 people with advanced triple-negative breast cancer, head and neck cancer, …

Researchers are testing whether adding simvastatin, a common cholesterol drug, to standard chemotherapy helps women with triple negative breast cancer. The trial enrolls 26 women with advanced triple negative breast cancer who are scheduled for eight cycles of AC-T chemotherapy. …

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (MK-2870) to the immunotherapy pembrolizumab can better prevent breast cancer from coming back in people with triple-negative breast cancer who still had tumor after initial treatment. About 1,5…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…

This phase 3 trial tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with advanced triple-negative breast cancer (TNBC) live longer without their cancer growing. Participants have TNBC that cannot be treated with current PD(L)1 immunotherapie…

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This phase II trial tests whether adding an experimental drug called INBRX-106 to the immunotherapy pembrolizumab (Keytruda) can shrink tumors in people with stage II or III triple-negative breast cancer before they receive standard chemotherapy. The study will enroll 12 adults w…

This early-phase study tests a new drug called BG-C9074, designed to target and kill cancer cells in people with advanced solid tumors that have not responded to standard treatments. The study will first find the safest dose, then test it alone or with other cancer drugs. About 3…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This study tests a new drug called BMS-986507, alone or with other cancer medicines, in adults with advanced lung or breast cancer that has spread. The goal is to check safety, side effects, and how well the drugs work. About 416 participants will receive different combinations t…

This early-phase trial tests whether freezing a tumor (cryoablation) can boost the immune response to the drug pembrolizumab in people with metastatic or locally advanced triple negative breast cancer. About 30 participants will be randomly assigned to receive either the combinat…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), given alone or with pembrolizumab, helps people with advanced triple-negative breast cancer live longer or keep their cancer from growing. About 1,000 adults whose cancer has spread and who have not had prior…

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…

This phase 3 trial is testing whether adding a targeted therapy called Sacituzumab tirumotecan (Sac-TMT) to standard chemotherapy and immunotherapy (pembrolizumab) can better eliminate cancer before surgery in people with high-risk, early-stage triple-negative or hormone-receptor…

This phase 2 trial is testing whether adding a targeted drug called patritumab deruxtecan to standard immunotherapy and chemotherapy can improve outcomes for people with high-risk early-stage triple-negative or hormone receptor-low positive breast cancer. About 372 participants w…

This early-stage trial tests an investigational cancer vaccine called ITI-5000 in 60 people with stage II-III triple-negative breast cancer who have finished standard treatment. The vaccine uses self-amplifying RNA to teach the immune system to attack cancer cells. The study firs…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This study tests whether combining radiation therapy with three drugs (platinum chemotherapy, adebrelimab, and bevacizumab) can control brain metastases from triple-negative breast cancer. About 58 adults aged 18-70 with this specific type of advanced breast cancer will receive t…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This study tests whether adding a personalized vaccine (made from unique tumor proteins) to a combination of chemotherapy and two immunotherapy drugs can better control metastatic triple-negative breast cancer. About 70 participants will be randomly assigned to receive the vaccin…

This study tests whether a combination of two drugs (sacituzumab govitecan and pembrolizumab) given after surgery works better than standard treatments to prevent breast cancer from coming back. It is for people with triple negative breast cancer who still have cancer cells in th…

This Phase 3 trial tests whether a combination of two drugs, trastuzumab rezetecan and adebrelimab, can prevent breast cancer from returning in people with triple negative breast cancer who still have cancer cells after initial chemotherapy and surgery. The study compares this ne…

This phase 2 trial tests whether adding the experimental drug evexomostat (SDX-7320) to standard chemotherapy (eribulin) works better than chemotherapy alone for people with metastatic triple-negative breast cancer who also have metabolic dysfunction (like insulin resistance). Th…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…

This Phase 2 trial tests whether adding an antiangiogenic drug to standard chemotherapy helps people with relapsed or metastatic triple-negative breast cancer. Participants receive albumin-bound paclitaxel alone, or combined with either apatinib mesylate (a pill) or bevacizumab (…

This phase II trial is testing whether giving a shorter, stronger course of radiation before breast surgery is safer and works better than giving it after surgery for people with non-metastatic breast cancer. The study will enroll 120 participants with different breast cancer typ…

This study tests whether giving a different antibody-drug conjugate (ADC) to people with advanced breast cancer who have already tried an ADC can still shrink tumors or slow the disease. About 160 participants will receive one of several ADCs or a targeted pill. The goal is to se…

This study tests whether adding tocilizumab, an anti-inflammatory drug, to standard chemotherapy improves outcomes for people with metastatic triple-negative or ER-low breast cancer. Researchers will compare the combination to chemotherapy alone in 168 Black and non-Black patient…

This pilot study tests whether adjusting chemotherapy based on early PET scan results can improve outcomes for people with stage 2 or 3 triple negative breast cancer. Participants receive four cycles of chemotherapy plus the immunotherapy drug pembrolizumab. A PET scan after the …

This phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…

This study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…

This early-stage trial tests a new drug called CT-202 in people with advanced triple-negative breast cancer, colorectal cancer, or bladder cancer that has come back or spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells that have a pro…

This trial tests whether an experimental drug called ProAgio, which targets blood vessels that feed tumors, can safely and effectively combine with the chemotherapy gemcitabine for people with metastatic triple-negative breast cancer. The study includes adults who have already tr…

This study looks at whether taking vitamin D supplements during standard chemotherapy can help more tumors disappear in people with triple-negative breast cancer who are low in vitamin D. About 50 participants will receive vitamin D plus chemotherapy, and researchers will compare…

This early-stage trial tests an experimental oral drug called NKT5097 in adults with advanced solid tumors, especially breast cancer. The drug works by breaking down two proteins that help cancer cells grow. Researchers want to find the safest dose and see if it can shrink tumors…

This early-phase study tests a new drug called BL-B01D1 in people with advanced stomach or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any side effects. About 96 adults aged 18 to 75 will take part, and r…

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…

This study compares a combination of two drugs (elacestrant and capecitabine) to capecitabine alone in people with advanced estrogen receptor-positive breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to one of the two t…

This early-stage trial is testing a new type of immune cell therapy for people with advanced cancers that have a specific protein called KK-LC-1. The cancers being studied include stomach, breast, cervical, and lung cancer. Participants will receive chemotherapy followed by a sin…

This early-phase study is testing two drugs together — alpelisib and pembrolizumab — in people with metastatic breast cancer or melanoma that has spread to the brain or other organs. The main goal is to find a safe dose and see what side effects occur. Up to 50 adults whose cance…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This trial explores whether people with early-stage triple-negative breast cancer and high levels of tumor-infiltrating lymphocytes (TILs) can safely skip a class of chemotherapy drugs called anthracyclines, which are effective but can harm the heart. Participants receive 12 week…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This phase 2 study is testing fluzoparib, a daily pill, as a maintenance therapy for people with advanced triple-negative breast cancer whose disease was controlled by platinum chemotherapy. The trial will enroll 72 participants with or without BRCA gene mutations. The goal is to…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This trial tests whether a personalized exercise program, done at home before breast cancer surgery, can improve physical fitness and influence the body's immune and inflammatory responses. Women with newly diagnosed luminal B or triple-negative breast cancer who are about to rec…

This Phase 3 trial is testing whether a new drug called datopotamab deruxtecan (Dato-DXd), given alone or with another drug called durvalumab, works better than standard chemotherapy for people with a certain type of advanced triple-negative breast cancer (PD-L1 positive). About …

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…

This study looks at how well sacituzumab tirumotecan (SKB264) works, either alone or with other treatments, in people with advanced HER2-negative breast cancer that has spread or come back. It includes two groups: those with triple-negative breast cancer and those with hormone re…

This study tests whether adding a new drug called BEBT-209 to standard chemotherapy can shrink tumors and help people with advanced triple-negative breast cancer live longer. About 446 women aged 18 to 75 will be randomly assigned to receive either BEBT-209 plus two chemo drugs o…

This study asks whether a dose-dense chemotherapy combination called CMF (cyclophosphamide, methotrexate, and fluorouracil) can be a practical alternative to the standard AC regimen (doxorubicin and cyclophosphamide) for people aged 70 and older with early-stage breast cancer. Th…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This phase 2 trial tests whether injecting the experimental drug INT230-6 directly into the tumor before standard chemotherapy and immunotherapy can improve outcomes for people with early triple-negative breast cancer (TNBC). About 61 participants will be randomly assigned to rec…

This study tests whether adjusting cancer drug doses for people with the Duffy null blood trait can reduce treatment delays and dangerous fevers. About 90 participants with multiple myeloma or triple-negative breast cancer will receive standard chemotherapy with modified dosing g…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body …

This study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…

This trial tests an experimental oral drug called TT-702 in people with advanced solid tumors. The drug works by blocking a protein that tumors use to hide from the immune system. The study aims to find the safest dose of TT-702 when given alone and in combination with an immunot…

This early-phase trial tests a new drug called ZEN003694 combined with immunotherapy (pembrolizumab) and chemotherapy (nab-paclitaxel) in 57 people with advanced triple-negative breast cancer. The goal is to find a safe dose and see if the combo can shrink tumors or slow the canc…

This study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…

This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This study tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy in about 500 people with advanced triple-negative or ER-low breast cancer who cannot receive immunotherapy. The drug is designed to target and kill cancer cells while sparing hea…

This early-stage trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed. The goal is to find…

This study tests whether adding a fasting-mimicking diet and exercise to standard chemotherapy and immunotherapy can improve treatment results for people with early-stage triple negative breast cancer. About 356 participants will be randomly assigned to receive either the lifesty…

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This phase 2 trial is testing whether the investigational drug datopotamab deruxtecan (Dato-DXd) can safely and effectively treat HER2-negative breast cancer that has spread to the brain. The study enrolls adults with metastatic breast cancer who have brain metastases that are ei…

This study tests whether adding ivermectin (a drug used for parasitic infections) to standard immunotherapy drugs (balstilimab or pembrolizumab) can shrink tumors in people with metastatic triple-negative breast cancer. The trial has two phases: first, finding the safest dose of …

This phase 3 trial is for people with early-stage triple-negative breast cancer who had a complete response to chemotherapy plus the immunotherapy drug pembrolizumab before surgery. It compares continuing pembrolizumab for 27 weeks after surgery versus simply watching and waiting…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This study tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with early-stage triple-negative breast cancer. About 34 participants will receive the combination every three weeks for six cycles, then undergo surgery. …

This study tests a vaccine called STEMVAC, given with chemotherapy, for people with a type of advanced breast cancer (triple-negative) that has spread. The vaccine is designed to teach the body's immune system to find and destroy cancer stem cells. About 20 adults with PD-L1 nega…

This trial is testing an oral version of the chemotherapy drug paclitaxel, given after standard intravenous chemo, for people with triple-negative breast cancer. The study aims to find the safest and most effective dose of the oral paclitaxel. Participants will receive four cycle…

This phase 3 trial is testing whether a targeted drug called sacituzumab govitecan (Trodelvy), alone or combined with the immunotherapy pembrolizumab (Keytruda), can effectively treat low-risk triple-negative breast cancer before surgery. The study aims to see if these drugs can …

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This early-phase trial is testing a new combination of three drugs—cyclophosphamide, axatilimab, and retifanlimab—in people with metastatic triple negative breast cancer that has stopped responding to standard treatments. The main goal is to find the safest dose of the new combin…

This early-stage trial is testing a new type of targeted radiation therapy for people with advanced pancreatic, lung, breast, or colorectal cancers. The treatment uses a radioactive drug that seeks out cancer cells to deliver radiation directly, aiming to kill them while sparing …

This phase 2 trial is testing a drug called ivonescimab in people with a specific type of breast cancer called invasive lobular carcinoma that has spread and no longer responds to hormone therapy. The study includes 29 adults whose cancer is either hormone-receptor positive or tr…

This early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 parti…

This early-stage trial is testing a new type of immune cell therapy called CAR-T cells that target a protein called B7-H3 on triple-negative breast cancer cells. The cells also have a safety switch to stop them if needed. Up to 42 adults whose cancer has returned or not responded…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This phase 2 trial is for people with early-stage triple-negative breast cancer that has a high level of immune cells (TILs) in the tumor. It tests whether some patients can safely skip chemotherapy and just be monitored, while others receive a combination of the immunotherapy dr…

This phase 3 trial is testing whether patients with early-stage triple-negative breast cancer who have a complete response to standard chemotherapy plus the immunotherapy drug pembrolizumab can safely stop pembrolizumab early instead of continuing it for an additional six months.…

This trial is testing an experimental drug called AT-1965 in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then seeing whether the drug can shrink tumors. About 100 participants will…

This early-phase study tests a new drug, ASP1002, in adults with advanced solid tumors that have high levels of a protein called claudin 4. The main goals are to check the drug's safety, find the best dose, and see how well people tolerate it. Participants receive the drug throug…

This phase II trial is testing whether combining BL-B01D1, a targeted drug, with a PD-1 monoclonal antibody can shrink tumors in people with advanced triple-negative breast cancer that cannot be surgically removed or has spread. The study enrolls about 52 adults aged 18 to 75 who…

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This early-stage study is testing a new oral drug, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The drug is given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. Abo…

This phase IIa trial tests a combination of a dendritic cell vaccine (targeting HER2/HER3 proteins) and the immunotherapy drug pembrolizumab (Keytruda) in 23 women with breast cancer that has spread to the brain. The vaccine aims to train the immune system to attack cancer cells,…

This phase 2 study is testing a drug called sacituzumab govitecan, alone or with pembrolizumab, given before surgery to people with localized triple-negative breast cancer. The goal is to see if these drugs can eliminate all cancer cells in the breast and lymph nodes before surge…

This trial tests SPEDOX-6, a version of the chemotherapy drug doxorubicin wrapped in a protein shell, in people with advanced solid tumors such as soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, and certain pancreat…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This study tests a two-step approach for people with liver metastases from triple-negative breast cancer, melanoma, or colorectal cancer. First, doctors use heat or cold to destroy some liver tumors, which may release cancer signals that train the immune system. Then, patients re…

This early-phase trial tests the safety and best dose of a new drug combination—pidnarulex plus trastuzumab deruxtecan—in people with advanced breast cancer and other solid tumors that have the HER2 protein. The study enrolls 36 adults whose cancer has spread or cannot be surgica…

This study is for people with a type of breast cancer called triple-negative that has come back after treatment. The researchers want to see if adding a drug called bevacizumab to the usual combination of pembrolizumab and paclitaxel works better. About 44 adults who have already…

This early-phase trial is testing whether combining two drugs, naxitamab and sacituzumab govitecan, is safe and effective for people with metastatic triple-negative breast cancer. The study aims to find the best dose and check for side effects in 31 adults whose cancer has spread…

This early-phase study tests a new drug called PYX-201 in people with advanced solid tumors that have come back or spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 330 adults with certain breast, head and neck, or other cancers are being…

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This phase II trial is testing whether patients with early HER2-positive or triple-negative breast cancer who had a complete response to pre-surgery treatment and have no cancer DNA in their blood can safely receive less therapy after surgery. The goal is to reduce side effects w…

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This phase 2 trial is testing whether a simple blood test that looks for tumor DNA (ctDNA) can help doctors decide when to switch treatments in people with metastatic triple-negative breast cancer. The study compares standard care with a strategy where ctDNA results guide an earl…

This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard…

This early study tests an experimental drug called XB010, alone or combined with the immunotherapy pembrolizumab, in people with advanced solid tumors (like lung, breast, or head and neck cancers) that have stopped responding to other treatments. The main goals are to find a safe…

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This study tests whether adding two immunotherapy drugs (CDX-1140 and CDX-301) to standard chemotherapy (PLD) is safe and helps control metastatic HER2-negative breast cancer. About 30 people with advanced cancer that has not responded to other treatments will take part. The goal…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This early-stage study tests a new drug called BAL0891, given alone or with chemotherapy or immunotherapy, in people with advanced solid tumors or acute myeloid leukemia (AML) that has come back or not responded to treatment. The main goals are to find a safe dose and check for s…

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…

This early-stage trial is testing a new drug called THE-0504 in 30 adults with advanced solid tumors, including lung, colon, stomach, breast, and pancreatic cancers. The main goal is to see if the drug is safe and to find the best dose. Researchers will also watch for any signs t…

This Phase II trial tests whether adding a PD-L1 antibody (adebrelimab) to a specific chemotherapy regimen (VEX) — with or without radiation — can delay cancer growth in people with advanced triple-negative breast cancer. About 150 participants will be randomly assigned to one of…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This phase II trial is testing a drug called ARX788 in 36 people with HER2-low breast cancer that has spread or cannot be removed. ARX788 is an antibody-drug conjugate that delivers a toxin directly to cancer cells with the HER2 protein. The main goal is to see how many patients'…

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

This study tests a new drug called MORAb-202 that targets a protein (folate receptor alpha) found on some cancer cells. It is for people with ovarian, endometrial, non-small cell lung, or triple-negative breast cancer. The trial has two parts: first to find the safest dose, then …

This phase 2 trial tests whether adding the beta-blocker propranolol to the immunotherapy drug pembrolizumab can help shrink tumors in people with metastatic triple-negative breast cancer that has stopped responding to checkpoint inhibitors. About 37 adults with advanced, unresec…

This phase 2 trial is testing a combination of three drugs—alpelisib, L-NMMA, and nab-paclitaxel—in people with a rare, aggressive form of breast cancer called metaplastic breast cancer (MpBC) that has spread or is locally advanced. The study aims to find the best dose and see if…

This early-phase study is testing an experimental drug called CLR 125 in 60 people with advanced triple-negative breast cancer that has not responded to prior treatments. The main goals are to find the safest and most effective dose and to understand what side effects occur. Part…

This early-stage trial tests a new drug called MST-0312, designed to help the body's immune system fight cancer more effectively. It is being studied alone or with another cancer drug (pembrolizumab) in people with several types of solid tumors, including lung, melanoma, bladder,…

This study tests whether a combination of two drugs, sacituzumab tirumotecan and bevacizumab, can shrink or control brain tumors in people with triple-negative breast cancer that has spread to the brain. About 24 adults whose cancer cannot be removed by surgery or radiation will …

This study is testing whether adding an immunotherapy drug called QL1706 to standard chemotherapy after surgery can help prevent high-risk triple-negative breast cancer from coming back. About 59 women with this aggressive cancer type will receive the combination treatment, follo…

This Phase 2 trial at Fudan University tests several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see which combinations best eliminate all signs of cancer (pathological complete response) based on each tumor's specific subtype. Ab…

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This early-phase trial is testing a personalized oral DNA vaccine called NECVAX-NEO1 in 28 people with triple-negative breast cancer. The vaccine is given alongside standard chemotherapy and an immunotherapy drug before and after surgery. The goal is to see if it is safe and help…

This study is for people with metastatic triple-negative breast cancer that has not responded to one prior treatment. It tests two combinations of drugs: one with sacituzumab govitecan and nivolumab, and another that adds a third drug, relatlimab. The goal is to see which combina…

This phase II trial is testing a combination of three drugs—QL1706 (an immunotherapy), anlotinib (a targeted therapy), and nab-paclitaxel (chemotherapy)—as a first treatment for advanced triple-negative breast cancer. The study will enroll 34 women and aims to see if the combo ca…

This study is for women with a type of advanced breast cancer called triple-negative breast cancer that does not have the PDL1 protein. It tests whether adding an immunotherapy drug (durvalumab) to a targeted chemotherapy (datopotamab deruxtecan) works better than the chemotherap…

This early-phase trial tests a new cell therapy for people with advanced triple negative breast cancer that has stopped responding to standard treatments. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying a …

This early-phase trial tests AVA6000, a chemotherapy drug that is designed to activate only in tumors, potentially reducing side effects. About 158 adults with advanced solid tumors (like breast, ovarian, or salivary gland cancer) will receive the drug intravenously. The main goa…

This study tests whether using focused ultrasound (HIFU) to destroy tumors, with or without an immune-boosting drug (PD-1 inhibitor), before standard chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer. About 58 participants will receive on…

This phase 2 trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. The study will enroll 46 participants and measure how many achieve a complete response (no c…

This early-phase trial is testing whether adding dupilumab (an eczema and asthma drug) to standard immunotherapy and chemotherapy can safely improve outcomes for people with locally advanced triple-negative breast cancer. About 15 participants will receive the combination before …

This early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is …

This early-phase trial tests a new drug, UCB4594, in people with advanced solid tumors that haven't responded to standard treatments. The drug is a monoclonal antibody that targets a protein called HLA-G on cancer cells, potentially helping the immune system attack them. The stud…

This study tests whether a high-fiber diet (20-30 grams per day) combined with mind-body support can help women with triple-negative breast cancer undergoing immunotherapy and chemotherapy. Sixty participants will either receive online group training or a simple nutrition flyer. …

This phase 3 trial tests whether the drug SKB264 works better than standard chemotherapy as the first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. About 524 participants will be randomly assigned to receive eith…

This study tests a 12-18 week treatment without anthracyclines (a type of chemo that can harm the heart) for people with triple-negative breast cancer who already have heart conditions or are at high risk for heart damage. The treatment combines two chemotherapy drugs (carboplati…

This study tests whether combining two drugs, sacituzumab govitecan and atezolizumab, can clear leftover cancer cells in the breast or lymph nodes of people with triple negative breast cancer. About 40 participants who still have cancer after standard chemotherapy will receive th…

This phase 2 trial is testing whether adding low or high dose radiation to standard chemotherapy and the immunotherapy drug pembrolizumab can improve treatment for people with node-positive triple negative breast cancer. Thirty-two participants will be randomly assigned to receiv…

This program provides early access to an experimental drug called leronlimab for people with advanced triple-negative breast cancer who have run out of standard treatments. Participants must be adults with stage IIIB or IV cancer that has worsened despite prior therapy. The goal …

This study tests whether adding pembrolizumab to sacituzumab govitecan helps control metastatic triple-negative breast cancer that is PD-L1-negative. About 110 adults with advanced TNBC will be randomly assigned to receive either the combination or sacituzumab alone. The goal is …

This study tests whether combining tamoxifen (a hormone blocker) with a targeted form of chemotherapy (liposomal doxorubicin) can shrink tumors in people with advanced triple-negative breast cancer that has spread or cannot be removed by surgery. The trial enrolls 30 adults who h…

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This Phase 3 trial tests whether a combination of three drugs—camrelizumab, apatinib, and eribulin—works better than standard chemotherapy for advanced triple-negative breast cancer. The study will enroll 246 women aged 18 to 70. Researchers will measure how long the cancer stays…

This phase 2 trial is testing whether a fasting-mimicking diet (a low-calorie, plant-based diet) can improve the effectiveness of standard chemoimmunotherapy for early or locally advanced triple-negative breast cancer. About 80 women aged 18 to 70 will follow the diet for five da…

This study is for people with a high-risk type of breast cancer (triple-negative) who still have cancer cells left after standard treatment and surgery. Researchers will use a special blood test (ctDNA) to look for tiny traces of cancer DNA that scans might miss. If the test find…

This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…

This study tests whether adding a drug that blocks a certain immune cell (CSF-1R inhibitor) and radiation to standard immunotherapy (pembrolizumab) can help the body fight high-risk triple-negative breast cancer more effectively. About 35 women with this aggressive cancer will re…

This study tests whether a drug called pegfilgrastim (Neulasta) can prevent a dangerous drop in white blood cells and fever (febrile neutropenia) in women with triple-negative breast cancer. The 40 participants receive the drug after each round of AC chemotherapy, which follows e…

This study tests whether adding a drug called tetrathiomolybdate (TM) to standard chemotherapy (capecitabine) can reduce the risk of cancer spreading in people with high-risk triple-negative breast cancer. The trial has two parts: first, a small safety phase, then a larger random…

This study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy can help shrink tumors or slow disease in people with advanced HER2-negative breast cancer. About 92 adults whose cancer has worsened after prior treatments will receive the combinat…

This phase II trial tests whether adding high-dose radiation to standard immunotherapy (pembrolizumab) and chemotherapy can help control metastatic triple-negative breast cancer that is PD-L1 positive. About 29 participants with at least two sites of metastatic disease will recei…

This study tests a new drug called JSKN016 against standard treatments for people with advanced triple-negative breast cancer that has not responded to at least two prior therapies. The goal is to see if JSKN016 can slow cancer growth or extend survival. About 364 adults aged 18 …

This Phase 2 trial tests two different drug combinations—JS207 plus 9MW2821 or JS207 plus albumin paclitaxel—as a first treatment for people with recurrent or metastatic triple-negative breast cancer. The study will enroll 80 participants to see if these combinations can shrink t…

This study tests whether two drugs, pembrolizumab and lenvatinib, can shrink brain tumors in people with breast cancer, lung cancer, or other solid tumors that have spread to the brain. About 87 participants will receive the combination therapy. The goal is to see how well the tr…

This study tests whether giving treatments based on the genetic makeup of a person's triple-negative breast cancer can shrink tumors or slow the disease. It is for people whose cancer has not responded to standard therapies. About 120 women will receive a treatment chosen specifi…

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This early-stage trial is testing an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific protein (folate receptor alpha) on their cells. The study has two parts: first, finding the safest dose, an…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target multiple proteins on breast cancer cells. It is for people with advanced or metastatic breast cancer, including HER2-positive and triple-negative types, who have not responded to s…

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This phase 2 trial tests two oral drugs, bicalutamide and abemaciclib, in 53 women with a specific type of advanced breast cancer called androgen receptor-positive triple-negative breast cancer. The goal is to see if the combination can stop the cancer from growing for at least 1…

This study tests whether adding an oral probiotic (Biolosion) to standard chemotherapy before surgery can help eliminate more cancer cells in women with early-stage triple-negative breast cancer. About 192 participants will receive either standard treatment alone or standard trea…

This study tests a more personalized chemotherapy plan for women with early-stage triple-negative breast cancer. The treatment is adjusted based on immune system activity in the tumor and imaging results. The goal is to see if a lighter chemo can still be effective, reducing side…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will enroll about 61 participants and…

This study tests whether adding the drug VEGFR BP102 to standard chemotherapy (nab-paclitaxel) helps people with a specific, hard-to-treat form of advanced triple-negative breast cancer (called BLIS subtype). About 134 participants who have not had prior treatment for metastatic …

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) to fight advanced breast cancer, including HER2-positive and triple-negative types. About 60 adults whose cancer has not responded to standard treatments will receive cells tailored to their t…

This early-phase trial is testing a new drug called bulumtatug furvedotin (BFv) in 52 people with triple-negative breast cancer that has come back or spread to other parts of the body. Participants must have already received certain types of chemotherapy and antibody-drug conjuga…

This study tests whether adding the drug AK112 to standard chemotherapy (nab-paclitaxel) helps people with advanced triple-negative breast cancer live longer without their cancer growing. About 416 adults who have not had prior treatment for advanced disease will be randomly assi…

This study is for people with certain types of breast cancer (HER2-positive or triple-negative) who have a complete response to initial drug therapy. It tests whether they can safely skip surgery and only receive radiation, or skip radiation if surgery shows no cancer left. For a…

This study tests whether adding the drug sarilumab to chemotherapy (capecitabine) can eliminate tiny amounts of cancer left behind after standard treatment in people with triple negative breast cancer, a very aggressive type. The goal is to prevent the cancer from coming back and…

This study tests a new approach for people with triple-negative breast cancer whose tumors don't shrink after standard chemotherapy. Participants receive targeted radiation to the tumor followed by immunotherapy (toripalimab) plus more chemo. The goal is to see if this combinatio…

This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin and paclitaxel) can improve outcomes for people with stage 1 triple-negative breast cancer. The study will enroll 28 participants at MD Anderson Canc…

This study tests whether adding the drug QL1706 to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 30 patients with stage II or III disease. Participants receive the combination in two phases over about 8 months, then have surgery. T…

This study tests whether giving a very focused, high-dose radiation treatment (SBRT) to all visible cancer spots can delay the cancer from getting worse in people with breast or lung cancer that has spread to 1-5 places. About 145 participants will either receive standard care al…

This early-stage study is testing a new drug called OTS167PO in people with advanced breast cancer that has come back or spread. The main goal is to find the safest dose and understand side effects. About 70 women aged 18 and older will take part.

This study tests whether adding an antifungal drug (posaconazole) to standard immunotherapy and chemotherapy can help more women with triple-negative breast cancer achieve a complete response before surgery. About 72 women with early-stage, high-risk disease will be randomly assi…

This early-stage trial is testing a new drug called PQ203 in about 80 adults with advanced solid tumors, including triple-negative breast cancer, that have not responded to standard treatments. The drug is given as a weekly intravenous infusion. The main goals are to check safety…

This study is for people with advanced breast cancer that is androgen receptor-positive (AR+) and either triple-negative or low in estrogen receptors. It tests whether the drug enzalutamide, alone or combined with mifepristone, can control the cancer as well as standard chemother…

This study tests a new drug called MBRC-201 in people with advanced solid tumors (prostate, breast, colorectal, lung, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly …

This study tests a specific chemotherapy combination (epirubicin + cyclophosphamide followed by docetaxel + carboplatin) in 85 Nigerian women with triple-negative breast cancer. The main goal is to see how many women have no cancer left in their breast or lymph nodes after treatm…

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…

This study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive/HER2-negative breast cancer. About 34 adul…

This study tests a new drug called LBL-024, either by itself or combined with chemotherapy (albumin-bound paclitaxel), in people whose triple negative breast cancer has come back or spread. The goal is to see if the drug can shrink tumors and control the disease. About 220 adults…

This early-stage trial tests whether giving the drug bortezomib first can make metastatic triple-negative breast cancer more sensitive to two other drugs (pembrolizumab and cisplatin). About 20 women with advanced breast cancer that has already been treated with standard chemothe…

This study tests a new drug called MR001 in people with advanced triple-negative breast cancer (TNBC) whose cancer has worsened after standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 42 participants wil…

This phase 2 trial is testing whether giving a short course of radiation (SBRT) and two injections of the immunotherapy drug pembrolizumab (Keytruda) before standard chemotherapy can improve outcomes for people with stage 2 or 3 breast cancer. The study aims to see if this combin…

This study tests whether using a patient's genetic profile to customize radiation doses can better control triple negative breast cancer after lumpectomy. About 86 participants will receive genomically guided radiation therapy. The goal is to prevent cancer from returning in the …

This study tests whether giving immunotherapy every 6 weeks instead of every 3 weeks works as well for advanced triple-negative breast cancer. The goal is to keep the cancer under control while reducing side effects and improving quality of life. About 416 participants whose canc…

This early-phase study tests an experimental vaccine made from a patient's own immune cells, designed to target two cancer-related proteins (HER2 and HER3). The vaccine is injected directly into the tumor alongside standard chemotherapy before surgery. The goal is to find the saf…

This study tests whether combining two drugs, niraparib and dostarlimab, can control advanced cancers that have spread to the brain. It includes 120 adults with certain cancer types like BRCA-mutated or lung cancers. The goal is to see if the treatment shrinks or stabilizes brain…

This early-stage trial is testing a treatment called X-PACT for people with advanced head and neck cancer, breast cancer, soft tissue sarcoma, or melanoma that has not responded to standard treatments. X-PACT involves injecting a drug called methoxsalen directly into the tumor an…

This study tests a different dose and schedule of the drug sacituzumab govitecan (Trodelvy) in people with advanced triple-negative breast cancer that has not responded to prior treatment. The trial has two phases: phase 1 checks safety and the best dose, and phase 2 measures how…

This study tests whether adding targeted radiation (SBRT) to standard chemotherapy and immunotherapy can improve outcomes for people with early-stage triple-negative breast cancer (TNBC). TNBC is harder to treat than other breast cancers, and this combination aims to boost the im…

This phase II trial is testing a combination of two drugs—Sac-TMT (a targeted chemotherapy) and KL-A167 (an immunotherapy)—given before surgery to 40 people with triple-negative breast cancer. The goal is to see if the combo can eliminate or shrink tumors enough to improve long-t…

This early-phase trial is testing a personalized vaccine made from a patient's own tumor, given alone or with immune-boosting drugs (pembrolizumab or ipilimumab), for triple negative breast cancer. The goal is to see if the vaccine is safe and can train the immune system to attac…

This study is testing whether adding calorie restriction to a precise, high-dose radiation treatment (SABR) before surgery can shrink breast tumors more than radiation alone. About 80 adults with early-stage breast cancer will be randomly assigned to either standard dietary advic…

This phase 3 trial tests whether adding an anti-vascular drug to standard chemotherapy can help prevent cancer from returning in people with a specific, aggressive type of triple-negative breast cancer. About 764 women with stage II to III cancer will receive either the combinati…

This study tests whether adding two targeted drugs (sintilimab and bevacizumab) to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 37 women with stage II-III disease. The main goal is to see how many patients have no cancer left at s…

This phase 2 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can improve outcomes for women with triple-negative breast cancer. About 35 participants will receive the combination, then undergo surgery. The main goal is to…

This early-phase trial is testing a radioactive drug called 225Ac-TR2205 in 15 women with advanced triple-negative breast cancer that has spread. The main goal is to see if the drug is safe and tolerable, and to measure how much radiation reaches tumors. It is too early to know i…

This early-stage study tests a new drug called NM6603 in about 30 adults with advanced solid tumors (mainly colorectal or triple-negative breast cancer) who have run out of standard options. The main goal is to find the safest dose and check how the drug moves through the body. P…

This early-stage study tests an experimental oral drug called DPTX3186 in 40 adults with advanced solid tumors (like colorectal, gastric, lung, or triple-negative breast cancer) that are linked to a specific cell signal called Wnt. These participants have no other approved treatm…

This study tests whether MRI scans can identify triple-negative breast cancer patients who respond well to initial chemotherapy and immunotherapy, allowing them to skip the second, more toxic phase of treatment. About 54 participants will receive four cycles of a chemo-immunother…

This study tests an experimental oral drug called JAB-2485 in adults with advanced solid tumors, including certain breast and lung cancers. The goal is to see if the drug is safe and can shrink tumors. About 102 participants will receive the drug, and researchers will monitor sid…

This study tests a combination of three drugs (atezolizumab, vinorelbine, and cyclophosphamide) in people with advanced triple-negative breast cancer that has spread. Participants have already received immunotherapy before. The goal is to see if this new mix can shrink tumors or …

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This phase 3 trial is testing whether a new combination of drugs (SHR-A1811 plus SHR-1316) works better than the current standard treatment for a specific type of advanced breast cancer called PD-L1-positive triple-negative breast cancer. The study will enroll 400 women whose can…

This phase 2 trial is testing whether women with certain aggressive breast cancers (triple negative or HER2-positive) can safely avoid breast surgery if their tumors disappear completely after a combination of chemotherapy and radiation. The study will enroll 200 women and follow…

This study tests a new treatment called GO306, a modified virus designed to infect and destroy cancer cells. It is for adults with advanced solid tumors (like breast, colon, or kidney cancer) that have not responded to standard therapies. The main goal is to check the safety of t…

This phase 3 trial is testing whether adding the antibiotic moxifloxacin to standard chemotherapy (gemcitabine and carboplatin) helps people with metastatic triple-negative breast cancer live longer without their cancer growing. About 228 participants will receive either the anti…

This study tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (Camrelizumab) given before surgery can eliminate all cancer in patients with early triple-negative breast cancer. About 64 participants will receive this trea…

This study tests whether adding two drugs (sacituzumab govitecan and zimberelimab) to precise brain radiation can help people with metastatic triple negative breast cancer that has spread to the brain. The trial will enroll 31 adults and compare the combination against sacituzuma…

This phase 2 trial is testing different ways to combine radiotherapy with the immunotherapy drug toripalimab and chemotherapy for people with advanced triple-negative breast cancer (TNBC). The goal is to find the best schedule that helps control the cancer longer. About 60 partic…

This study tests a new drug called tenalisib in 40 people with metastatic triple negative breast cancer (TNBC) who have already tried 1 to 3 other treatments. The goal is to see if tenalisib can shrink tumors or stop them from growing for at least 16 weeks. Researchers will also …

This study tests a new drug called MB0151 in adults with advanced solid tumors, including certain lung, breast, and neuroendocrine cancers. The goal is to check the drug's safety and see if it can shrink or control tumors. About 156 participants will receive the drug intravenousl…

This phase 2 trial is testing several drug combinations (including choline, sodium cromoglicate, efavirenz, and others) alongside immunotherapy to see if they can reverse resistance in triple-negative breast cancer that has progressed after prior immunotherapy. About 80 participa…

This early-phase study tests a new immunotherapy drug (QL1706) combined with short cycles of chemotherapy in 30 people with early-stage triple-negative breast cancer. The goal is to see if this approach can eliminate all signs of cancer before surgery. Participants receive either…

This phase 2 trial tests whether adding pembrolizumab (an immunotherapy) to capecitabine (chemotherapy) after standard treatment can prevent triple-negative breast cancer from coming back. It includes 220 adults who still have cancer after initial chemo-immunotherapy. Participant…

This study is the first to test AVZO-021, an oral drug that blocks a protein called CDK2, in people with advanced solid tumors. The trial will enroll about 430 adults with certain breast, ovarian, or other cancers. The goal is to find safe doses and see if the drug can shrink tum…

This study tests whether adding retinoic acid (a vitamin A derivative) to an immune checkpoint inhibitor can help shrink tumors or slow disease progression in people with HER2-negative breast cancer whose cancer stopped responding to prior immunotherapy. About 10 participants wil…

This early-phase trial is testing a radioactive drug called 177Lu-CTR-FAPI in 4 people with advanced pancreatic cancer that has not responded to standard treatments. The drug is given intravenously every 6 weeks for up to 4 doses. Researchers are checking for safety, how much rad…

This early-phase trial tests whether combining two oral drugs, neratinib and ruxolitinib, is safe and can shrink tumors in people with metastatic triple-negative breast cancer that has come back on the chest wall after chemotherapy. About 20 women will take the drugs daily, and d…

This study is for people with early-stage triple-negative breast cancer. It compares a shorter chemo-immunotherapy regimen without anthracyclines (a type of strong chemo) to the usual longer treatment. The goal is to see if the shorter approach works just as well while reducing s…

This study tests a new daily pill, VLS-1488, for people with advanced solid tumors that have not responded to other treatments. About 200 participants with specific cancers like ovarian, lung, or breast cancer will receive the drug to see if it is safe and shrinks tumors. The goa…

This study tests whether adding the drug darolutamide to standard chemotherapy and immunotherapy before surgery can shrink tumors more effectively in people with early-stage androgen receptor positive triple-negative breast cancer. About 51 participants will receive either standa…

This early-phase trial tests a new drug called STX-001, a self-replicating RNA that makes a protein to stimulate the immune system. It is injected directly into tumors, either alone or with the immunotherapy pembrolizumab (Keytruda). The study aims to find a safe dose and see if …

This study tests whether a structured nutrition and exercise program can improve the chance of a complete response to pre-surgery chemo-immunotherapy in women with triple-negative breast cancer. About 160 women who are not currently exercising or eating many fruits and vegetables…

This study is for adults with solid tumors that have certain genetic features (HRD/FAD) or are growing despite immunotherapy. The experimental drug CP-506 is designed to activate only in low-oxygen areas of tumors, potentially killing cancer cells while sparing healthy tissue. Th…

This early-phase study tests a personalized cell therapy for people with several types of advanced cancer that have spread and express a protein called NY-ESO-1. Participants receive a single infusion of their own immune cells that have been genetically modified to recognize and …

This study tests a new drug combination (invikafusp alfa plus sacituzumab govitecan) in people with advanced breast cancers that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and can shrink or control tumors. About 50 adults with tripl…

This study tests a drug called datopotamab-deruxtecan (Dato-DXd) in 20 people with triple-negative breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. Participants must have newly diagnosed or worsening brain metastases. The study i…

This Phase 3 trial is testing a new drug called ESG401 against standard chemotherapy for people with advanced triple-negative breast cancer that has spread or come back. The study will enroll about 504 participants to see if ESG401 can delay cancer growth and improve survival. It…

This phase 2 trial is testing whether women with HER2-positive or triple-negative breast cancer who have a complete response to chemotherapy can safely skip surgery or radiation. The study will enroll 152 women and monitor them for cancer recurrence, distant spread, or death. The…

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to at least one prior treatment. The therapy uses a patient's own tumor-fighting immune cells, which are modified in the lab to work better, and then gi…

This phase 2 trial compares two chemotherapy combinations given before surgery for triple-negative breast cancer. About 520 women will receive either nab-paclitaxel plus carboplatin or nab-paclitaxel plus epirubicin. The goal is to see which combo better eliminates cancer cells i…

This Phase 2 trial is testing two different chemotherapy combinations in 414 women with advanced triple-negative breast cancer (TNBC), a fast-growing type that lacks common treatment targets. One group gets nab-paclitaxel plus carboplatin, the other gets nab-paclitaxel plus capec…

This study tests A2B395, a donor-derived CAR T-cell therapy designed to target cancer cells while sparing healthy ones. It is for adults with advanced solid tumors like colorectal, lung, or breast cancer that have lost a specific immune marker. The trial has two phases: first to …

This early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…

This study is testing whether routine brain MRIs can find brain metastases in stage IV breast cancer patients who have no neurological symptoms. Researchers will scan 170 participants at the start and again at 6 months or when their cancer first progresses. The goal is to see how…

Researchers are studying whether a blood test called Guardant360 can measure how well cancer treatment is working in people with advanced lung, colorectal, or breast cancer. The test looks for tumor DNA that cancer cells release into the bloodstream. Participants give blood sampl…

This trial tests an experimental imaging agent called [68Ga]Ga-DWJ155 in adults with advanced cancers of the breast, lung, or stomach. The agent is designed to attach to tumor cells and show up on PET scans, helping doctors see where cancer has spread. Researchers will measure ho…

This early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…

This study tests a new radioactive tracer called 68Ga-DOTA-BPP, which targets a protein (ACE) found on some cancer cells. Researchers want to see if it can improve PET/CT imaging for people with triple-negative breast cancer, a type that can be harder to detect. The trial involve…

This early-phase study is testing whether a special PET scan tracer, originally used for prostate cancer, can detect metastatic triple negative breast cancer. Thirty women with advanced disease will receive both standard FDG PET and the new PSMA PET scan. The goal is to see if PS…

This study tests a new imaging system that uses light to monitor how breast cancer responds to chemotherapy before surgery. Researchers want to see if it can accurately predict when the cancer is completely gone. The study involves 15 women with specific types of breast cancer. I…

This study compares a special contrast-enhanced mammogram (CEDM+CEDBT) with standard breast MRI to see if it can accurately predict whether breast cancer has been eliminated by chemotherapy. About 30 women with locally advanced breast cancer will get 1-2 of these mammograms durin…

This pilot study is testing a new type of PET scan that uses a tracer called [68Ga]Ga-PentixaFor to see if it can detect metastatic triple-negative breast cancer as well as or better than the standard FDG PET scan. The study will enroll 12 patients with metastatic triple-negative…

This study is testing whether a special whole-body MRI scan can find breast cancer that has come back or spread to other parts of the body earlier than standard methods. Researchers will follow 145 women with aggressive breast cancer types (HER2+ or triple-negative) for five year…

This study is testing whether a new type of PET scan (68Ga-FAPI-46) can predict if triple-negative breast cancer will completely respond to chemotherapy plus immunotherapy before treatment begins. About 60 women with early-stage, high-risk breast cancer will get the scan before s…

This study is looking at whether a brain MRI can spot cancer that has spread to the brain in people with certain types of breast cancer (triple negative or HER2-positive, stage IIb or III) who have no symptoms. About 100 participants will get a contrast-enhanced brain MRI, give a…

This study tests a program called ICCAN that gives cancer patients extra help with social and economic needs, like finding resources and monthly check-ins. Researchers want to see if this support helps patients complete their cancer treatment and improves their quality of life, c…

This pilot study tests whether a nurse-led, group-based virtual coping program called RESTORE is feasible and acceptable for people who have finished treatment for triple-negative breast cancer. The program teaches skills like problem-solving, relaxation, and mindfulness to help …

This study tests a flexible palliative care program for people with advanced heart failure or certain cancers. The program adds more team members—like a social worker or nurse—as symptoms get worse. The goal is to improve quality of life and match care to each person's changing n…

This study tests if a steroid mouthwash can prevent or reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 100 adults with advanced breast or lung cancer will use the mouthwash and be monitored for 12 weeks. The goal is to see if this simple step…

This Phase 3 trial tests whether Nuvastatic 300 mg capsules can reduce the crushing fatigue that often comes with chemotherapy. About 250 women with metastatic triple-negative breast cancer will take either the supplement or a placebo three times daily for 60 days while continuin…

This trial tests a blended e-health program designed to help women with breast or gynecologic cancer cope with fear of their cancer returning or worsening. The program combines remote group sessions with online modules that teach skills to manage unhelpful thoughts and promote he…

This study tests whether eating only within an 8-hour window (time-restricted eating) can improve how well cancer treatments work and reduce side effects. It involves 100 Alaska Native and American Indian patients with breast or rectal cancer. Participants will follow the eating …

This study tests whether a home-based 'taste steering' program can improve food enjoyment for cancer patients undergoing chemotherapy. 201 adults with metastatic triple negative breast cancer, metastatic testicular cancer, or stage II-IV diffuse large B cell lymphoma will be rand…

This study tests whether a 10-week stress reduction program is doable and helpful for people with triple negative breast cancer. The program includes relaxation, coping skills, and social support, and also addresses basic needs like utilities or transportation. Researchers will m…

This study tracks how patients with metastatic triple-negative breast cancer feel during treatment with sacituzumab govitecan or standard chemotherapy. Researchers will measure changes in quality of life and symptoms using patient questionnaires. The goal is to see which treatmen…

This pilot study tests whether a supervised treadmill walking program can help people with early-stage triple-negative breast cancer who are receiving immunotherapy before surgery. The main goal is to see if patients can stick with the exercise routine. Researchers will also chec…

This study tests whether a 12-week MIND eating plan can reduce memory problems, fatigue, and other symptoms in women with stage II-III triple-negative breast cancer during chemotherapy. About 60 women will be randomly assigned to either the MIND diet or general health coaching, w…

This phase 2 trial tests whether a dexamethasone mouthwash can lower the chance of painful mouth sores (stomatitis) caused by the cancer drug datopotamab deruxtecan. About 60 people with advanced breast or lung cancer will use the mouthwash for the first five days of each treatme…

This study tests whether a digital platform called Cureety TechCare can improve quality of life and reduce hospitalizations for people with metastatic triple-negative breast cancer starting first-line treatment. Participants will regularly report symptoms through the platform, wh…

This study collects spinal fluid, blood, saliva, and tumor samples from 139 adults with HER2-positive or triple-negative breast cancer that has spread to other organs but not yet to the brain. Researchers will analyze these samples for tumor DNA that might predict when the cancer…

This study is for people with metastatic breast cancer, including estrogen receptor-positive and triple-negative types. It uses biomarkers from tumors and blood to guide treatment choices, comparing how long the cancer stays controlled on the new therapy versus the previous one. …

This study looks at how bacteria inside tumors and the immune cells around them affect how well triple-negative breast cancer responds to chemotherapy and immunotherapy. Researchers will collect tumor, blood, and stool samples from 30 women before and during treatment. They want …

This study aims to understand why some breast cancers become resistant to therapy. Researchers will analyze tumor and blood samples from 320 people with HER2-positive, hormone receptor-positive, or triple-negative breast cancer. The goal is to identify changes in cancer cells tha…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study is looking at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. These leftover cells, called minimal residual disease (MRD), can sometimes cause the cancer to come back. The study will follow 900 breast cancer …

This study is testing a new approach called Functional Precision Oncology for people with triple-negative or HR-low/HER2- breast cancer at high risk of early recurrence. Researchers will create personalized tumor models (in mice and lab dishes) from each patient's cancer to find …

This study tests whether a computer algorithm called ENLIGHT can help find better drug matches for people with advanced breast cancer that has stopped responding to standard treatments. About 175 adults with triple-negative or hormone-resistant breast cancer will have their tumor…

This study aims to build a prediction model for early triple-negative breast cancer (TNBC) using data from the UPGRADE-TNBC study. By combining clinical information, imaging, pathology, and molecular data, and using a meta-learning approach, the researchers hope to identify which…

This registry tracks up to 1,500 people with triple negative breast cancer or inherited genetic mutations (like BRCA). Researchers will study how often these mutations occur, how patients respond to chemotherapy, and long-term survival. The goal is to better understand the diseas…

This pilot study tests whether a special type of PET/MRI scan can monitor how triple-negative breast cancer responds to immunotherapy. Twenty patients will get three scans over their first two treatment cycles. The results won't change their care but could help design larger stud…

This study tests a simple blood test (liquid biopsy) to see if it can tell which triple-negative breast cancer patients will benefit from the drug capecitabine after standard chemotherapy. About 40 adults with leftover cancer after chemo will give blood samples before and during …

The AURORA study is collecting tumor and blood samples from 1,300 people with metastatic breast cancer across Europe. By analyzing genetic changes in both the original and metastatic tumors, researchers hope to understand why some patients respond well to therapy while others do …

This study looks at whether regular blood tests (ctDNA monitoring) combined with a special type of PET scan can detect the return of triple negative breast cancer earlier than standard methods. About 450 women who finished treatment for early-stage triple negative breast cancer w…

This study tests whether a special PET scan that tracks Granzyme B—a molecule released by active immune cells—can predict how well immunotherapy works in people with advanced triple-negative breast cancer. Thirty participants will receive the scan before and after two cycles of i…

This study looks at 200 women with early-stage triple-negative breast cancer to find immune markers in tumors and blood that predict whether immunochemotherapy will work well. Researchers will compare those who have a complete response to those who don't, aiming to guide more per…

This study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…

This study is for people with metastatic triple-negative breast cancer who are already receiving the drug sacituzumab govitecan as part of their routine care. Researchers want to see how well the drug works in everyday practice and find biological markers (biomarkers) that predic…

This study reviews medical records of 600 people with HER2+ or triple-negative breast cancer who had chemotherapy and still had cancer in their lymph nodes. The goal is to see if skipping additional lymph node removal (axillary dissection) leads to more cancer coming back in the …

This study follows 100 people with stage III triple-negative breast cancer to see how standard treatments affect their quality of life. Participants fill out questionnaires about their well-being at nine time points and may give blood samples to track cancer DNA. The goal is to l…

This study looks at how a single session of aerobic exercise—either moderate or high intensity—affects breast cancer cells in the lab. Researchers will take blood from breast cancer survivors before and after exercise, then see if that blood slows the growth of breast cancer cell…

This study looks at how well standard chemotherapy works in people with triple-negative breast cancer, an aggressive type that lacks targeted treatments. Researchers will also measure tiny molecules called microRNAs and tumor DNA in the blood to see if changes can signal when the…

This pilot study is looking at how the immune system responds in people with early-stage triple negative breast cancer who receive standard chemotherapy plus the immunotherapy drug pembrolizumab before surgery. The goal is to see if certain immune markers in the blood or tumor ti…

This study looks at how immunotherapy drugs (anti-PD-1) affect bone strength in people being treated for cancer. Researchers will measure bone density and blood markers over a year in 25 patients. The goal is to understand if these treatments increase fracture risk, so doctors ca…

This study is testing new drug combinations for breast cancer to see which ones work best for different tumor types. It involves up to 5,000 people with early-stage or locally advanced breast cancer. Researchers use MRI scans and tissue samples before surgery to predict treatment…

This study takes tumor samples from people with triple-negative breast cancer, colorectal cancer, or ovarian cancer and grows them in mice. Researchers then test different drugs on these mouse tumors to see which ones might work best for each person. The goal is to provide person…

This study looks at whether a blood test can find tiny bits of tumor DNA (ctDNA) in people with early-stage triple-negative breast cancer. Researchers will collect blood samples before and during treatment to see if the test can help predict if the cancer might come back. About 7…

This study is for 500 adults with non-metastatic breast cancer who are about to start treatment like chemotherapy or targeted therapy before surgery. Researchers will collect tumor tissue, blood, and sometimes stool samples and MRI scans during treatment. The goal is to learn why…

This study takes tumor samples from women with aggressive breast cancers (triple-negative or luminal B) and grows them in mice to create patient-derived xenografts (PDX). The goal is to see how well these mouse models mimic the original tumors and to learn about tumor evolution a…

This study tests whether a computer-generated character (PERLA) can effectively educate cancer patients about genetic testing, compared to a human genetics counselor. Researchers will enroll 800 people with certain cancers, including breast, ovarian, pancreatic, and prostate canc…

This study takes small tumor samples from people with triple-negative breast cancer and grows them in the lab as 3D mini-tumors called organoids. Researchers will test different cancer drugs on these organoids to see which ones work best and look for clues that could predict a pa…

This study looks at whether it is possible to take multiple tissue samples (biopsies) from different tumor sites in people with metastatic breast cancer at different times during treatment. The goal is to learn how cancers change and become resistant to therapy. About 200 adults …

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…

This study looks at bacteria living in breast tumors of people with triple negative breast cancer. Researchers want to see if these bacteria can help predict who will respond well to chemotherapy and immunotherapy before surgery. The study will collect tumor samples before and af…

This study is for people with high-risk early breast cancer, including inflammatory breast cancer. Researchers want to see if clusters of tumor cells found in the blood can help predict how well treatment works and the chances of survival. About 130 participants will give blood s…

This study is for women with triple-negative breast cancer, either early-stage or advanced, who are receiving immunotherapy. Researchers want to see if changes in a simple blood marker called CRP can predict how well the treatment works. The goal is to find a way to personalize t…

This study is collecting tumor samples from 1,050 people with early or metastatic breast cancer to analyze fat storage and organelle properties in cancer cells. Researchers aim to create a detailed atlas of these features across different breast cancer subtypes. The goal is to be…

This study collects tumor and blood samples from over 1,000 people with certain cancers (ovarian, breast, head and neck, cervical, vulva, and sarcoma). Researchers will analyze the samples to find links between genetic changes, the immune system, and how the cancer behaves. Parti…

This study is for people with solid tumors that have spread to the brain. Researchers want to collect medical information and samples (like blood and spinal fluid) to better understand why and how brain metastases happen. The goal is to find new ways to treat or prevent them in t…

This study looks at whether combining four types of scans (ultrasound, mammography, MRI, and PET-CT) can accurately predict if triple-negative breast cancer has been completely eliminated by chemotherapy and immunotherapy. Researchers will also check blood markers to identify whi…

This study is looking at proteins called selenoproteins in people with triple-negative breast cancer (TNBC), a hard-to-treat type. Researchers will measure these proteins in tumor samples and blood from 300 patients and 100 healthy women. The goal is to see if selenoproteins can …

This study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their routine care. Researchers will collect blood samples and medical records to see how long the cancer stays controlled with each ADC treatmen…

This study looks at whether a person's mental state—like anxiety or depression—can influence how well immunotherapy works for triple-negative breast cancer. About 120 women will receive standard treatment, complete psychological surveys, and give blood and saliva samples. Researc…

This study takes small tumor samples from 240 women with invasive breast cancer who are scheduled for chemotherapy before surgery. Researchers will grow these samples into mini-tumors (organoids) in the lab to study each cancer's unique features. The goal is to see if these lab m…

This study looks at whether the phase of a woman's menstrual cycle when she starts chemotherapy affects how well the treatment works for breast cancer. Researchers will collect a blood sample from 100 premenopausal women with triple-negative breast cancer on the day they begin ne…

This study aims to develop a blood test that uses artificial intelligence to analyze tumor material in the blood of people with triple negative breast cancer. The goal is to better predict which patients need more chemotherapy after surgery and which can safely avoid it. Research…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help predict how well breast cancer responds to chemotherapy given before surgery. Researchers will take blood samples from 125 women with stage II or III breast cancer before, during, and after treat…